Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient

Int J Clin Pharmacol Ther. 2005 Dec;43(12):583-5. doi: 10.5414/cpp43583.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins / metabolism*
  • Antineoplastic Agents / metabolism*
  • Chromatography, High Pressure Liquid
  • Electrophoresis, Capillary
  • Humans
  • Indazoles / metabolism*
  • Neoplasms / blood
  • Neoplasms / metabolism*
  • Organometallic Compounds
  • Protein Binding
  • Ruthenium
  • Ruthenium Compounds / metabolism*
  • Spectrometry, Mass, Electrospray Ionization
  • Transferrin / metabolism*

Substances

  • Albumins
  • Antineoplastic Agents
  • Indazoles
  • Organometallic Compounds
  • Ruthenium Compounds
  • Transferrin
  • indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))
  • Ruthenium